Clinical trials: Central Line Infection
- Condition Central Line Infection
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Catheter-Related Infections
Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
This is an Intermediate-Size Expanded Access, Open-Label Study for Use of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Central Line Associated Bloodstream Infection.
- Trial name
- MLK (NCT04513821)
- Testing
- Mino-Lok Therapy (MLT)
- Where
- 30 sites in United States, Puerto Rico
- Sponsor
- Leonard-Meron Biosciences, Inc.
Central Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN)…
- Trial name
- NCT06822426
- Testing
- (taurolidine and heparin) catheter lock solution, Heparin
- Where
- 24 sites in United States, Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- CorMedix Therapeutics
Catheter-related Bloodstream Infection
Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
The EAP for DefenCath is designed to provide access to a broader population of adult and pediatric patients using catheters for various serious medical conditions.
- Trial name
- NCT06707480
- Testing
- Taurolidine and Heparin
- Sponsor
- CorMedix Therapeutics
Infection
Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters
The purpose of this study is to determine whether treatment with topical omiganan is more effective than treatment with topical povidone-iodine in preventing local catheter site infections and catheter colonization in patients…
- Trial name
- NCT00231153
- Testing
- Omiganan 1% gel, Povidone-Iodine 10%
- Where
- 57 sites in United States, France and 2 more
- Volunteers
- 1,859 people
- Sponsor
- Cadence Pharmaceuticals
Catheter-related Infections
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution as…
- Trial name
- NCT02901717
- Testing
- Mino-Lok, Antibiotic lock
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 144 people
- Sponsor
- Leonard-Meron Biosciences, Inc.
Sepsis, Bacteremia
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis.
- Conditions
- Sepsis, Bacteremia, Fungemia
- Trial name
- NCT00027248
- Testing
- MBI 226
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- BioWest Therapeutics Inc